The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials

医学 内科学 肺炎 入射(几何) 肺癌 不利影响 随机对照试验 荟萃分析 相对风险 科克伦图书馆 化疗 肿瘤科 胃肠病学 置信区间 光学 物理
作者
Guofu Lin,Yuan Xu,Hai Lin,Dongyong Yang,Lin Chen,Linlin Huang,Xiaoshan Su,Yingxuan Xu,Yiming Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:99: 108011-108011 被引量:4
标识
DOI:10.1016/j.intimp.2021.108011
摘要

Immune checkpoint inhibitors (ICIs) have shown a significant efficacy for patients with non-small cell lung cancer (NSCLC). However, checkpoint inhibitor pneumonitis (CIP) is a rare but severe and life-threatening adverse event. Hence, we performed a systematic review and meta-analysis to evaluate the incidence and risk of CIP in patients with NSCLC. Pubmed, Embase, Cochrane Library and ClinicalTrials.gov (http://clinicaltrials.gov/) were searched up to December 15, 2020. Studies regarding all-grade and high-grade pneumonitis were included. The data was analyzed using meta-packages of R 3.6.0. A total of sixteen randomized controlled trials including 9500 patients were identified for further evaluation. The overall incidence of all-grade and high-grade CIP was 4.17% and 2.02%, respectively. Compared with conventional chemotherapy, patients treated with ICIs significantly increased risk of all-grade (RR: 4.11, p < 0.0001) and high-grade (RR: 3.16, p < 0.0001) pneumonitis. Subgroup analysis showed the ICIs combined with chemotherapy was associated with a higher incidence of CIP than monotherapy alone (6.03% vs 3.32%, p = 0.01). And the rate of death owing to CIP was higher than chemotherapy-mediated pneumonitis. There were a higher incidence and risk of pneumonitis with the application of ICIs when compared with chemotherapy. Higher mortality rate of pneumonitis was more frequent in ICIs group. Thus, early detection, proper administration and optimal management are needed for physicians prevent potentially CIP deterioration.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
了一完成签到,获得积分10
1秒前
1秒前
英姑应助大方安白采纳,获得10
1秒前
dong应助slx采纳,获得10
2秒前
里净完成签到,获得积分20
3秒前
星辰大海应助咻咻采纳,获得10
3秒前
瘦瘦的硕完成签到,获得积分20
4秒前
量子星尘发布了新的文献求助10
4秒前
wangnn发布了新的文献求助10
4秒前
木叶完成签到,获得积分10
5秒前
6秒前
6秒前
共享精神应助小琦无敌采纳,获得10
7秒前
7秒前
无语的y天完成签到,获得积分10
10秒前
英俊的铭应助蔡6705采纳,获得10
10秒前
清新的Q完成签到,获得积分10
10秒前
研友_VZG7GZ应助里净采纳,获得10
10秒前
vision0000完成签到,获得积分10
11秒前
Donk完成签到 ,获得积分10
11秒前
Lucas应助小火苗采纳,获得10
11秒前
plasmid完成签到,获得积分10
12秒前
笨笨紫霜发布了新的文献求助10
13秒前
14秒前
梨里完成签到,获得积分10
14秒前
YCW完成签到,获得积分10
15秒前
16秒前
个性楷瑞完成签到,获得积分10
17秒前
clock完成签到 ,获得积分10
17秒前
ZZZ完成签到,获得积分10
18秒前
lelele发布了新的文献求助10
19秒前
yyyy完成签到 ,获得积分10
19秒前
HY完成签到,获得积分10
20秒前
梨里发布了新的文献求助10
20秒前
李银锋完成签到,获得积分10
20秒前
韩涵发布了新的文献求助10
22秒前
小二郎应助伶俐绮采纳,获得10
24秒前
CCsci完成签到 ,获得积分10
24秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976058
求助须知:如何正确求助?哪些是违规求助? 3520294
关于积分的说明 11202245
捐赠科研通 3256804
什么是DOI,文献DOI怎么找? 1798471
邀请新用户注册赠送积分活动 877610
科研通“疑难数据库(出版商)”最低求助积分说明 806496